Life Sciences Hiring Intelligence.
FDA filings, clinical milestones, and regulatory enforcement — decoded into executive hiring demand before the mandate exists.
For executive search partners who want to see the hiring landscape before the market does. 22 intelligence entries across 3 life sciences subsectors — the predictive executive search business development intelligence that reveals where companies are under pressure to hire, why, and when, before a public posting appears.
- 22 intelligence entries across 3 life sciences subsectors
- 100% verifiable data — FDA, SEC, ClinicalTrials.gov filings
- Life sciences only — built for your subsector
- Pipeline model — every FDA stage mapped to hiring demand
- Why most BD in life sciences underperforms
- The Pipeline Progression Model
- The 4 intelligence categories
- Layering intelligence — where the power lives
- Biopharma — drug pipeline & commercial
- MedTech — device clearance & launch
- CDMO — capacity, clients & expansion
- 4 Growth indicators
- 8 Pipeline indicators
- 6 Distress indicators
- 4 Event-based indicators
- Request a free intelligence brief
- See what this looks like for your desk
- Book a call with Kawsar
Every drug, device, and biologic moves through a regulatory pipeline that is publicly documented — from IND filing to PDUFA decision, from 510(k) submission to FDA clearance, from facility expansion to cGMP inspection. Each stage creates a predictable wave of executive hiring demand: clinical operations at Phase I, commercial leadership at Phase III, quality and regulatory overhaul after an FDA enforcement action. The search partners who decode these milestones before they become job postings don't compete on contingency — they arrive with predictive, executive search business development intelligence that earns retained mandates.
Why Most Business Development in Life Sciences Search Underperforms
Life sciences executive search is a sophisticated, high-value practice. The business development model behind it, for most firms, is not.
The typical BD cycle works like this: a search partner monitors LinkedIn and job boards, reaches out when a VP or C-level role appears, and competes against three to five other firms who spotted the same posting on the same day. Alternatively, they attend JPMorgan Healthcare or BIO and hope a conversation turns into a mandate months later. Or they rely on a referral network built over years — effective, but unpredictable and impossible to scale.
These methods all share the same structural weakness: they are reactive. By the time a job posting appears, the company has already spent weeks trying to fill the role internally. By the time a referral comes in, the hiring pressure may have been building for months. And by the time a conference conversation matures, a competitor who understood the regulatory calendar has already locked up the engagement.
The gap is not talent, relationships, or execution. The gap is timing — and specifically, the absence of a systematic way to identify executive hiring demand before it becomes visible to the broader market.
That gap is exactly what predictive hiring intelligence closes. Not by replacing relationships and expertise, but by ensuring your first conversation happens at the moment of greatest urgency — and arrives with enough regulatory and operational context that the prospect immediately sees you as a strategic partner, not another agency email to archive.
The Pipeline Progression Model: Why Life Sciences Is Uniquely Predictable
What makes life sciences different from virtually every other executive search vertical is the regulatory pipeline. A drug cannot go to market without moving through a defined series of FDA-governed stages. A medical device cannot be sold without a clearance or approval pathway. A contract manufacturer cannot accept new clients without validated capacity and cGMP compliance.
Each stage in these pipelines creates specific, predictable functional hiring needs — and those stages are documented in publicly accessible databases. This is the structural advantage that life sciences search partners have over every other vertical: the data that predicts executive demand already exists. It is published by the FDA, the SEC, ClinicalTrials.gov, and state regulatory agencies. It simply needs to be decoded.
Take a biopharma company as an example. When it files an IND and enters Phase I clinical trials, ClinicalTrials.gov shows the filing, the study protocol, and the timeline. Within 60-90 days of that milestone, the company needs a VP of Clinical Operations, a Director of Biostatistics, and a Head of Drug Safety — roles that did not exist on any job board the week before the filing. A search partner tracking IND acceptances doesn't need to wait for the posting. They know the hiring is coming because the regulatory milestone makes it inevitable.
This pattern repeats at every pipeline stage. Phase II success triggers commercial planning hires — a Chief Commercial Officer, a VP of Market Access, a head of HEOR — because the company now has proof-of-concept and needs to prepare for launch. A PDUFA date 10 months away means launch-readiness hiring is already underway: field medical directors, national sales directors, distribution and supply chain VPs. The pipeline is a hiring calendar. The FDA publishes it. Almost no search partners read it.
The same logic applies to MedTech, where a 510(k) submission tells you the company is 90-180 days from needing a commercial launch team, and to CDMOs, where a facility expansion filing means the company will need plant directors, quality VPs, and operations leadership 12-18 months before the first batch ships.
The Subsector × Function Matrix
Life sciences executive search is not organised the way healthcare search is. In healthcare, a search partner typically specialises by facility type — a hospital C-suite desk, a behavioural health desk, a post-acute desk. The facility type defines the practice.
Life sciences search is organised around a subsector × function matrix. A search partner specialises in a subsector — Biopharma, MedTech, or CDMO — and then focuses on specific functional lanes within that subsector: Commercial, R&D/Clinical, Regulatory/Quality, Manufacturing/Operations, Medical Affairs, or Corporate. A partner might describe their practice as "I place commercial leaders in oncology biopharma" or "I recruit quality and regulatory executives for Class III device companies."
The subsector distinction matters because each subsector operates under a different regulatory framework, follows a different pipeline progression, and generates a different set of hiring intelligence. A PDUFA date drives hiring in biopharma but is meaningless in devices. A 510(k) clearance creates commercial urgency in MedTech but doesn't exist in pharma. A CDMO facility expansion triggers an entirely different talent profile than a drug approval launch.
Part II of this guide maps three subsectors — Biopharma, MedTech, and CDMO — each with their functional areas, roles in scope, the decision-makers who feel the hiring pressure, and the specific intelligence that applies. Part III is the full intelligence library, with tracking instructions for every entry.
The Four Categories of Hiring Intelligence
The 22 intelligence entries in this guide are organised into four categories. Each category reflects a different source of executive hiring pressure and a different timeline for engagement.
Distress intelligence identifies companies under immediate regulatory, quality, or safety pressure — an FDA Warning Letter, a clinical hold freezing the pipeline, a Class I device recall, a Complete Response Letter rejecting a drug application. These are not optional problems. The company must respond with leadership changes in quality, regulatory, manufacturing, or clinical operations, often within 15-day FDA response deadlines.
Pipeline intelligence tracks the regulatory milestones in the progression model above. An IND acceptance means the company needs to build a clinical operations team. A Phase II to Phase III transition triggers a commercial scale-up. A PDUFA date approaching means launch readiness hiring is underway. Every milestone is public, every timeline is knowable, and every resulting hire is predictable — often 6-12 months before a job posting appears.
Growth intelligence tracks financial and capacity expansion that funds executive hiring. A Series B funding round, an IPO filing, a CDMO announcing a new facility build, a licensing deal that gives a company rights to commercialise a new product. These indicators tell you hiring is coming 3-6 months before the first job post appears.
Event-based intelligence tracks structural changes that trigger leadership transitions on a known timeline. M&A, IPO filings, mass layoffs, and licensing deals. When a pharma company acquires a biotech, the integration creates VP and Director-level roles across regulatory, commercial, and operations — typically within 90 days of close.
Layering Intelligence: Where the Real Power Lives
A single intelligence entry tells you something is happening at a company. Layered intelligence tells you exactly what they need, why they need it now, and why their internal process is likely to fail — the foundation of a retained search mandate.
Consider the difference between these two outreach approaches:
Reactive: "I noticed your Head of Regulatory Affairs role has been posted for a few weeks. We specialise in regulatory placements in biopharma and would love to help." That is valid — but surface-level. Any search partner with a LinkedIn Recruiter licence could have sent it.
Intelligence-led: "Your company received 510(k) clearance for your cardiac monitoring device last month. Your Head of Commercial role has been open for six weeks — which suggests the internal search hasn't closed it. And your most recent SEC filing shows a $45M Series C raised specifically to fund US commercialisation. Based on typical post-clearance timelines, you're likely looking at a 90-day window to have your commercial leadership in place before your launch sequence falls behind."
That is three intelligence entries layered on one company. The 510(k) clearance says the product is market-ready. The open role says internal recruitment has stalled. The funding round says the capital is committed. Together, they give you what no job board, referral network, or conference relationship can provide: predictive executive demand before it becomes visible to the market.
This is the model that wins retained and exclusive mandates — because the search partner isn't reacting to a posting. They're arriving with intelligence that demonstrates they understand the company's regulatory position, its commercial timeline, and the executive leadership gap standing between where the company is and where it needs to be.
Board of Directors and CEO for C-suite searches. CEO or CSO for VP-level R&D and clinical roles. CEO or CCO for commercial leadership. CFO for finance and operations. Never approach HR at a <50-person biotech — the CEO or CSO is your buyer.
CEO for C-suite and VP-level searches. VP of R&D or CTO for engineering. VP of Quality or VP of Regulatory for quality and regulatory hires. In smaller MedTech startups (<100 employees), the CEO or founder is almost always the direct buyer.
CEO or COO for site-level and VP-level searches. VP of Operations or Site Director for plant-level leadership. PE operating partner for platform build and integration roles — a significant proportion of CDMO search is driven by PE portfolio companies.
When a life sciences company closes a significant funding round — Series A ($10-30M), Series B ($30-80M), or Series C ($80M+) — the capital is almost always earmarked for specific milestones: advancing a drug into clinical trials, building a commercial team, scaling manufacturing. The hiring that follows is predictable by round size and company stage. A search partner who arrives within weeks of the announcement, understanding what the capital is for, is positioned as a strategic partner rather than another agency.
Why This Matters
Venture funding in life sciences is milestone-driven. A Series A typically funds IND-enabling studies and the first clinical hires. A Series B funds Phase II/III trials and the clinical operations build-out. A Series C or later funds commercial launch preparation or manufacturing scale-up. The capital raise is public — and the hiring plan that follows is predictable.
The operational impact depends on round size. A $15M Series A at a pre-clinical biotech might mean 5-10 hires, mostly scientific. A $75M Series B at a clinical-stage company means 20-40 hires across clinical operations, regulatory, and early commercial. A $120M Series C means full commercial launch team and VP-level hires across every function. Each round creates demand for progressively more senior roles.
Roles & Who to Contact
Roles This Intelligence Triggers: CEO (Series A — founder may step aside), CSO, VP of Clinical Development, Head of Clinical Operations, VP of Regulatory, VP of CMC, CFO (post-Series B), CCO (post-Series C), VP of Sales, VP of Manufacturing.
Who to Approach: CEO directly at Series A/B stage companies. Chief People Officer or VP of HR at Series C and later. Board member or lead investor for CEO and C-suite searches. At pre-Series B companies, the CEO makes almost every senior hire personally.
How to Track It
Fierce Biotech publishes a free fundraising tracker (fiercebiotech.com) that covers VC rounds above $50M in biopharma. For smaller rounds and MedTech, check SEC EDGAR for Form D filings (sec.gov/cgi-bin/browse-edgar — filter by form type "D" and SIC codes 2830-2836 for pharma, 3841-3842 for devices). Form D is filed within 15 days of a first sale of securities and includes the offering amount.
Cross-reference funding announcements with ClinicalTrials.gov to see what stage the company's pipeline is at — this tells you what the money is for and what roles will follow. Check LinkedIn for company headcount growth trend and open roles. Processing takes 1-2 hours per week.
Cross-reference with Intelligence 2 (IND Filing) or Intelligence 15 (510(k) Submission). A company that just raised Series B AND filed an IND is building its clinical team right now — that's 3-5 senior hires in the next 90 days.
When a CDMO announces a facility expansion — a new manufacturing plant, a new production line, or a significant capacity increase — it creates a wave of hiring across operations, quality, manufacturing, and site leadership. A new facility needs 100-500+ employees, with 10-20 VP and Director-level roles filled through executive search.
Why This Matters
The CDMO industry is experiencing a historic expansion cycle driven by reshoring, biosimilar demand, and the growth of cell & gene therapy manufacturing. In 2025 alone, over $24 billion was invested in CDMO facility expansion and acquisition.
A facility expansion announcement is a 12-24 month indicator. The most senior roles (Site Director, VP of Quality) are typically the first to be filled — often through retained search — because they need to be in place to oversee facility build-out and commissioning.
Roles & Who to Contact
Roles This Intelligence Triggers: Site Director, VP of Operations, VP of Quality, Plant Director, Director of Production, Director of Validation, Director of Facilities Engineering, VP of Supply Chain, Head of Process Engineering.
Who to Approach: CEO or COO of the CDMO. VP of Operations for site-level leadership. PE operating partner for PE-backed CDMOs.
How to Track It
ContractPharma (contractpharma.com) covers CDMO facility expansions. PharmaSource and Pharmaceutical Technology also cover expansions. Set Google Alerts for "CDMO expansion" and "CDMO facility" to catch announcements.
Cross-reference expansion announcements with the company's LinkedIn page to assess current site leadership. Processing takes 1-2 hours per week.
Check whether the CDMO recently received an FDA Warning Letter (Intelligence 7) at another facility. A CDMO expanding while also dealing with quality issues at an existing site will be hiring quality leadership at both locations.
When a CDMO wins a major new client contract or secures a significant capacity agreement — particularly for biologic manufacturing, cell therapy, or sterile injectables — the contract creates immediate hiring demand across production, quality, and project management.
Why This Matters
CDMO client contracts specify production timelines, batch quantities, and quality standards. A new contract for blockbuster biologic drug manufacturing might require 50+ additional staff within 6 months.
The hiring urgency depends on the contract size and the CDMO's current capacity utilisation. A CDMO operating at 85%+ capacity that wins a major new contract has no choice but to hire aggressively.
Roles & Who to Contact
Roles This Intelligence Triggers: Director of Client Services, Director of Project Management, Production Manager, Quality Control Director, Director of Analytical Development, Batch Release Director, Key Account Director.
Who to Approach: VP of Operations or COO for production and quality roles. VP of Business Development for client services roles. CEO for strategic hires.
How to Track It
ContractPharma covers major CDMO contract wins. Company press releases announce partnerships. For publicly traded CDMOs, quarterly earnings calls discuss new client wins.
Monitor industry news and quarterly earnings. Processing takes 1-2 hours per week.
Layer with Intelligence 20 (Facility Expansion). A CDMO that wins a major client contract AND announces a facility expansion is in full growth mode.
When a CDMO achieves GMP certification for a new production line or capability — particularly for advanced therapies like cell & gene therapy, mRNA, or ADCs — it indicates the facility is ready to take on new client work. This creates hiring demand for specialised manufacturing, quality, and process development staff with niche expertise.
Why This Matters
GMP certification is the regulatory prerequisite for commercial manufacturing. A CDMO that achieves GMP certification for a cell therapy line can now bid for cell therapy manufacturing contracts — but only if it has the specialised team.
The certification reveals the CDMO's strategic direction. A CDMO investing in mRNA manufacturing capability is positioning for long-term demand. Understanding the strategic bet helps you identify the specific expertise the company will need.
Roles & Who to Contact
Roles This Intelligence Triggers: Director of Cell Therapy Manufacturing, Head of Process Development, Director of Quality Control (advanced therapies), Director of Analytical Development, Viral Vector Manufacturing Director, mRNA Production Director.
Who to Approach: VP of Operations or CTO for specialised manufacturing roles. CEO for strategic hires. VP of Business Development for commercial roles.
How to Track It
FDA Establishment Registration Database lists registered manufacturing sites and their capabilities. New registrations indicate new GMP lines.
ContractPharma and industry news cover major GMP certifications. Processing takes 1-2 hours per month.
Layer with Intelligence 21 (New Client Win). A CDMO that achieves GMP certification AND announces a client contract for that capability has confirmed demand.
When the FDA accepts a company's Investigational New Drug (IND) application, the company transitions from preclinical research to human clinical trials. This is the single biggest inflection point in a biotech's life — it triggers the build-out of an entire clinical operations team that didn't exist before. The IND acceptance is trackable through ClinicalTrials.gov, often before the company announces it publicly.
Why This Matters
Before IND acceptance, a biotech is a science project — a handful of PhD researchers, a CSO, and a CEO. After IND acceptance, it becomes a clinical-stage company that needs to run human trials under FDA oversight. This requires a fundamentally different team: clinical operations managers, medical monitors, biostatisticians, regulatory affairs specialists, clinical trial managers, and often a VP of Clinical Development to lead the programme.
The hiring surge is immediate and substantial. A company going from preclinical to Phase I typically needs to hire 8-15 people in clinical and regulatory functions within 6 months. These are specialised roles with limited talent pools, which is exactly why search firms get involved. The company often has no internal HR capability to recruit these roles — the CEO has been doing everything.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Clinical Development, Head of Clinical Operations, Medical Director / Medical Monitor, Director of Biostatistics, Clinical Trial Manager, CRA Manager, Director of Regulatory Affairs, VP of CMC.
Who to Approach: CEO directly — at this stage, the CEO approves every hire. CSO for scientific and medical roles. Board member or lead investor for VP-level searches.
How to Track It
ClinicalTrials.gov (clinicaltrials.gov) is the primary tracking source. The FDA requires registration of clinical trials within 21 days of enrolling the first participant. Search by sponsor name, condition, or use the API to filter for newly registered Phase I studies. A new Phase I registration from a previously preclinical company is effectively an IND acceptance indicator.
Filter by "First Posted" date to see the most recent registrations. Cross-reference the sponsor company with Fierce Biotech or BioSpace for the IND acceptance announcement. Check LinkedIn for the company's current headcount — if they're under 30 people and just got an IND accepted, the clinical hiring wave is imminent. Processing takes 2-3 hours per week.
Layer with Intelligence 1 (Funding Round). A company that just raised Series A AND filed an IND has both the capital and the regulatory green light. The clinical hiring wave starts immediately.
When a drug advances from Phase II to Phase III trials, the company transitions from proving the drug works to preparing it for market. Phase III is the most expensive stage of drug development ($50-300M), and the company must simultaneously build the commercial infrastructure to launch the drug if approved. This is when Chief Commercial Officers, VP of Sales, Market Access directors, and large field teams get hired.
Why This Matters
Phase III is the point of no return in biopharma. The company has invested years and hundreds of millions proving the drug's safety and efficacy in Phase I and II. Moving to Phase III means the data was strong enough to justify a pivotal trial — and the board has approved the budget to run it. This is a bet-the-company moment for clinical-stage biotechs.
The commercial build-out starts 18-24 months before expected approval. The company needs a Chief Commercial Officer to design the launch strategy, a VP of Market Access to negotiate payer contracts, Medical Science Liaisons to build KOL relationships, and a VP of Sales to design the field force. These are retained-search-level roles — $300K-500K base compensation — and the company is competing with every other late-stage biotech for the same talent.
Roles & Who to Contact
Roles This Intelligence Triggers: Chief Commercial Officer (CCO), VP of Sales, VP of Marketing, VP/Director of Market Access, Director of Managed Markets, MSL Director, Head of HEOR, VP of Medical Affairs, Director of Commercial Operations.
Who to Approach: CEO for CCO search. CCO (if already hired) for VP-level commercial roles. Head of Medical Affairs or CMO for MSL leadership. CFO for finance and commercial operations roles.
How to Track It
ClinicalTrials.gov is the primary source. Search for Phase III studies by sponsor name and filter by "First Posted" date to find recently initiated Phase III trials. The transition from Phase II to Phase III is also announced in company press releases and SEC filings (10-K/10-Q reports include pipeline stage updates).
For a broader view, filter ClinicalTrials.gov for all newly registered Phase III studies in the past 30-60 days. Cross-reference sponsors with their current commercial team on LinkedIn — if the company has no CCO, no VP of Sales, and just started Phase III, the commercial hiring wave is imminent. Processing takes 2-3 hours per month.
Layer with Intelligence 5 (PDUFA Date). A company in Phase III with a projected PDUFA date 18-24 months out is in the sweet spot for commercial team build. If they also just closed a funding round (Intelligence 1), all three indicators layered means the company has the pipeline, the timeline, and the capital.
When a company submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA, it has completed clinical development and is seeking marketing approval. The FDA has 60 days to accept or refuse the filing, and 10-12 months to render a decision. The filing triggers the final phase of launch preparation — medical affairs expansion, sales force hiring, manufacturing scale-up, and market access negotiations.
Why This Matters
An NDA/BLA filing is the most public, verifiable, and time-bound indicator in biopharma. The FDA announces the filing acceptance on its newsroom page. The PDUFA (decision) date is set — usually 10 months for a standard review or 6 months for a priority review. Every stakeholder — the board, investors, employees — now knows exactly when the approval decision will come.
The hiring pressure intensifies because the company must have its launch team in place BEFORE the approval decision, not after. A sales force of 100-300 representatives needs to be recruited, trained, and deployed. Medical Science Liaisons need to be in the field building KOL relationships. Market access teams need payer contracts negotiated. Manufacturing needs to be scaled for commercial supply. Missing the launch window by even 30 days costs millions in lost revenue.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Sales (if not already hired), National Sales Director, Regional Sales Directors, Director of Sales Training, VP of Medical Affairs, MSL Director, Director of Commercial Operations, Head of Launch Excellence, VP of Manufacturing (commercial scale).
Who to Approach: CCO for sales and marketing leadership. CEO for any remaining C-suite gaps. VP of Medical Affairs for MSL expansion. VP of Manufacturing for supply chain and production scale-up roles.
How to Track It
FDA Newsroom (fda.gov/news-events/fda-newsroom) publishes NDA/BLA filing acceptances. The FDA's CDER and CBER approval tracking pages list all pending applications with their PDUFA dates. Company press releases and SEC 8-K filings also announce submissions.
Check the FDA newsroom weekly for new filing acceptances. Cross-reference with the company's LinkedIn page to assess current commercial team size — a company with an NDA accepted and fewer than 5 commercial employees is about to hire 20-50+ people. Processing takes 1-2 hours per week.
Layer with Intelligence 5 (PDUFA Date) to see the exact decision deadline. If the company also received a Priority Review designation, the timeline compresses to 6 months — hiring urgency doubles.
The Prescription Drug User Fee Act (PDUFA) date is the FDA's deadline to render a decision on an NDA/BLA. It is the most precisely timed hiring intelligence in all of life sciences — you know the exact date, months in advance, when a company will either get approval (and need to launch immediately) or receive a Complete Response Letter (and need to restructure). Reaching out 3-6 months before a PDUFA date positions you as the search partner who understands their timeline.
Why This Matters
A PDUFA date creates a binary outcome on a known date. If the drug is approved, the company must execute its launch plan immediately — sales representatives deploy, MSLs activate, manufacturing shifts to commercial supply. If the drug receives a CRL (rejection), the company restructures — see Intelligence 10. Either outcome creates hiring demand.
The 3-6 months before a PDUFA date is when launch readiness hiring peaks. The company is filling final gaps in the commercial team, standing up a sales training programme, and ensuring manufacturing capacity. Search partners who specialise in commercial launch talent are in highest demand during this window.
Roles & Who to Contact
Roles This Intelligence Triggers: Regional Sales Directors, District Sales Managers, MSLs, Director of Sales Training, Director of Launch Operations, Field Medical Directors, Director of Distribution/Trade, VP of Patient Services.
Who to Approach: CCO or VP of Sales for field force roles. VP of Medical Affairs for MSL and field medical roles. CEO for any remaining VP-level gaps.
How to Track It
Multiple free sources track PDUFA dates. The FDA's own page lists upcoming decision dates. BiopharmaWatch (biopharmawatch.com/PDUFA-calendar) maintains a free PDUFA calendar. Assyro (assyro.com/tools/pdufa-calendar) offers a free tier. RTTNews (rttnews.com/corpinfo/fdacalendar.aspx) and pdufa.bio both maintain free, updated PDUFA calendars.
Set a quarterly review to identify all PDUFA dates 3-6 months out. Cross-reference each company with their LinkedIn commercial team size and open roles. A company with a PDUFA date 4 months out and no VP of Sales is in urgent need of commercial leadership. Processing takes 2-3 hours per quarter.
Layer with Intelligence 4 (NDA/BLA Filed) for full context on the application timeline. If the company also announced a Priority Review designation, the PDUFA date is 4 months earlier than standard — urgency is even higher.
When the FDA approves a new drug, the company enters commercial launch mode. Any remaining gaps in the commercial team become immediate vacancies. Manufacturing shifts from clinical to commercial supply. Medical affairs expands for post-marketing commitments. For first-time launchers (clinical-stage biotechs getting their first approval), this is the largest single hiring event in the company's history.
Why This Matters
A novel drug approval is the most visible event in biopharma — it makes national news, moves stock prices, and announces to the entire industry that the company has transitioned from development to commercial. For search partners, the approval confirms that every commercial role the company hasn't filled yet becomes urgent.
First-time launchers are the highest-value targets. A clinical-stage biotech getting its first drug approved may need to double its headcount in 12 months. The company needs to build commercial operations, patient services, medical information, pharmacovigilance, and distribution — all from scratch. This is $2-5M in recruitment fees for the agencies that get in early.
Roles & Who to Contact
Roles This Intelligence Triggers: Any unfilled commercial roles accelerate. New roles created: Director of Patient Services, Director of Pharmacovigilance, Head of Medical Information, Director of Distribution/Trade, VP of Commercial Operations, Field Reimbursement Managers.
Who to Approach: CEO for strategic hires. CCO for commercial operations and field roles. VP of Medical Affairs for medical information and pharmacovigilance. CFO for finance and operations scale-up.
How to Track It
FDA Novel Drug Approvals page (fda.gov/drugs/new-drugs-fda-cder/novel-drug-approvals) is updated in real time when approvals are granted. This is the definitive source.
Check the page weekly. For each approval, identify the sponsor company and assess their current team via LinkedIn. First-time launchers with fewer than 100 employees are your highest-value targets — they need the most help and are most likely to engage retained search. Processing takes 30 minutes per week.
If you didn't reach out before approval, stack with Intelligence 1 (Funding). A newly approved drug company that also recently raised capital is in full hiring mode — and if their stock price rose on the approval news, they may raise additional capital specifically for commercial scale-up.
When a medical device company submits a 510(k) or PMA application to the FDA, the product is near the end of its development cycle and the company is preparing for commercial launch. The 510(k) pathway averages 90-120 days to clearance; PMA averages 180 days. This is when commercial team hiring begins. The submissions are publicly searchable in the FDA's 510(k) and PMA databases.
Why This Matters
A 510(k) or PMA submission confirms that the device has completed design verification, validation, biocompatibility testing, and (for PMA) clinical trials. The company has invested years and millions reaching this point. The submission is a commitment to commercialisation.
The timing advantage for search partners is significant. From submission to clearance can be as short as 90 days for a 510(k). If a company submits a 510(k) today and has no VP of Sales, they need one in the next 60 days. That's a retained search — there isn't time for contingency.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Sales, VP of Marketing, Director of Clinical Education, National Accounts Director, Director of Sales Operations, Director of Reimbursement/Health Economics, Regional Sales Managers.
Who to Approach: CEO or COO for VP-level searches. VP of R&D or CTO for technical sales roles. Founder for early-stage MedTech companies.
How to Track It
The FDA's 510(k) Premarket Notification Database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm) is searchable by applicant name, device name, product code, and date range. The PMA Database provides the same for PMA applications.
Search for recently submitted 510(k)s and PMAs by filtering for decision dates in the "pending" range. Cross-reference the applicant company with LinkedIn to assess commercial team readiness. Processing takes 2-3 hours per week.
Layer with Intelligence 1 (Funding Round). A device company that just raised a Series B AND has a pending 510(k) has both the capital and the product readiness.
When the FDA clears a 510(k) device or approves a PMA device, the company enters commercial launch mode. Any unfilled commercial roles become immediate vacancies. Manufacturing scales from prototype/pilot to commercial volume. For first-time device companies, this is the equivalent of a drug approval.
Why This Matters
FDA clearance/approval removes the last regulatory barrier to market. The company can now sell the device in the United States. The commercial team must deploy immediately.
For device companies that have been operating on pre-revenue R&D funding, clearance is also a financial inflection point. Revenue begins, follow-on funding becomes easier to raise.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Sales (if not filled during submission phase), Regional Sales Managers, Clinical Specialists, Director of Clinical Education, VP of Manufacturing (commercial scale), Director of Distribution, Director of Customer Service, VP of Regulatory Affairs (post-market).
Who to Approach: CEO for strategic hires. CCO or VP of Sales for field roles. VP of Operations for manufacturing and distribution scale-up roles.
How to Track It
FDA Recently Cleared 510(k)s page is updated regularly with new clearances. The PMA database shows approved devices.
Check weekly. For each new clearance, assess the company's commercial readiness via LinkedIn. Processing takes 30-60 minutes per week.
Layer with Intelligence 1 (Funding). A device company that just received clearance and recently raised capital has both the product and the resources.
When a device company begins a clinical evaluation study (required for PMA-class devices), it needs to build or expand a clinical affairs team. The study registration on ClinicalTrials.gov is your indicator.
Why This Matters
PMA devices (Class III, highest risk) require clinical trial data. The clinical evaluation is a 1-3 year process that requires dedicated clinical affairs staff.
Many MedTech companies, particularly smaller ones, lack established clinical operations teams. A company registering its first clinical study is likely building this function for the first time.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Clinical Affairs, Director of Clinical Studies, Clinical Study Manager, Biostatistician, Director of Regulatory Submissions (PMA-specific), Medical Monitor.
Who to Approach: CEO or VP of R&D. VP of Regulatory for regulatory submission roles.
How to Track It
ClinicalTrials.gov — filter for device studies by sponsor name or device type. Look for newly registered studies from device companies that don't have existing clinical affairs teams on LinkedIn.
Processing takes 1-2 hours per week.
Layer with Intelligence 1 (Funding). A device company that raised capital AND started a PMA clinical study has both the resources and the regulatory commitment.
When the FDA issues a Warning Letter to a life sciences company, it means the agency found serious regulatory violations during an inspection — and the company failed to correct them after the initial Form 483 observations. A Warning Letter is public, searchable, and almost always triggers leadership changes in quality, regulatory, and manufacturing. The company has 15 business days to respond with a corrective action plan, and the board and investors are watching.
Why This Matters
A Warning Letter is the FDA's formal escalation. It follows a failed inspection (Form 483) where the company's response was inadequate. The letter is published in full on the FDA website and typically names specific quality system failures: inadequate CAPA processes, contamination control deficiencies, data integrity issues, or manufacturing deviations.
The leadership impact is predictable. The VP of Quality or Director of Quality who oversaw the failed systems is almost always replaced within 90 days. If the violations are severe — data integrity, sterility failures — the VP of Manufacturing and VP of Regulatory may also be replaced. In CDMO settings, a Warning Letter can cause clients to pull their contracts, which triggers additional business development and operations leadership changes.
For search partners, Warning Letters are among the highest-conviction distress indicators because the company must demonstrate to the FDA that it has installed competent leadership to fix the problems. A "new VP of Quality with a track record of FDA remediation" is exactly the kind of hire that requires retained search.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Quality, Director of Quality Assurance, Director of CAPA, Director of Validation, VP of Regulatory Affairs, VP of Manufacturing, Quality Remediation Consultant (often converts to permanent), Chief Compliance Officer.
Who to Approach: CEO or COO — they are personally accountable for the FDA response. General Counsel if the letter involves data integrity or potential criminal referral. Board member or PE operating partner for portfolio company Warning Letters.
How to Track It
FDA Warning Letters database (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) is searchable by company name, date, issuing office, and subject. Letters are published within days of issuance.
Filter by CDER (drugs), CDRH (devices), and ORA (manufacturing) issuing offices to focus on life sciences companies. Check weekly. Cross-reference the company name with LinkedIn to assess current quality and regulatory leadership — if the VP of Quality has been in the role less than 6 months, they were likely hired to fix a prior issue and may not survive a second Warning Letter. Processing takes 1-2 hours per week.
Check whether the same company had Form 483 observations (Intelligence 8) in the prior 12 months. A company that received a Form 483, failed to remediate, and then got a Warning Letter is in deep regulatory trouble — the leadership changes will be more extensive and more urgent.
When FDA inspectors complete a facility inspection and find deficiencies, they issue a Form 483 listing specific observations. Unlike a Warning Letter, a Form 483 is the first formal notice — the company has an opportunity to correct the issues before escalation. But serious 483 observations — especially repeat findings or data integrity issues — trigger immediate quality leadership reviews and often result in VP/Director-level replacements within 60-90 days.
Why This Matters
Form 483 observations are issued at the conclusion of every FDA inspection where deficiencies are found. The observations range from minor documentation gaps to critical manufacturing failures. The severity and number of observations determine the company's response — and the likelihood of leadership changes.
Key triggers for leadership replacement: 5+ observations in a single inspection, repeat observations from a prior inspection (indicating failed remediation), data integrity findings (which the FDA considers the most serious), and sterility assurance failures in injectable drug or device manufacturing. Any of these patterns indicates that the current quality leadership has failed to maintain compliance.
Roles & Who to Contact
Roles This Intelligence Triggers: Director of Quality Assurance, Director of CAPA, Director of Validation, Quality Systems Manager, Director of Manufacturing Quality, Head of Compliance, Director of Sterility Assurance (for sterile manufacturing sites).
Who to Approach: VP of Quality or VP of Operations — they own the remediation response. CEO at smaller companies. Site Director at CDMO facilities.
How to Track It
FDA Inspection Classification Database (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-classification-database) provides inspection outcomes. Search by company name and date range. The classification — OAI (Official Action Indicated), VAI (Voluntary Action Indicated), or NAI (No Action Indicated) — tells you the severity. OAI inspections are most likely to trigger Warning Letters and leadership changes.
For the actual 483 observations, these are available through FDA's FOIA reading room or by FOIA request. However, many companies voluntarily disclose 483 observations in SEC filings (10-K risk factors) or press releases. Check the company's most recent 10-K for mentions of FDA inspections. Processing takes 2-3 hours per month.
Check whether a Warning Letter (Intelligence 7) follows within 6-12 months. If the company received a 483 and you see no leadership changes on LinkedIn within 90 days, the company may not be taking remediation seriously — which means a Warning Letter is likely coming, and the leadership overhaul will be even more extensive.
When the FDA places a clinical hold on a drug programme, all clinical trial activity stops. Patients stop being enrolled. Ongoing treatments may be suspended. The company's pipeline — often its only pipeline — is frozen. A clinical hold is a crisis event that triggers immediate leadership reviews in clinical development, safety, and regulatory affairs. For single-asset biotechs, a clinical hold can be existential.
Why This Matters
Clinical holds are imposed when the FDA determines there is an unreasonable risk to trial participants — serious adverse events, manufacturing contamination, inadequate informed consent, or protocol design failures. The hold remains in effect until the company satisfactorily addresses the FDA's concerns, which can take weeks to months.
The leadership impact depends on the reason for the hold. Safety-related holds (adverse events) typically trigger a review of the Chief Medical Officer and VP of Clinical Development. Manufacturing-related holds (contamination, sterility) trigger quality and manufacturing leadership changes. Protocol-related holds may lead to changes in the biostatistics and regulatory teams.
For single-asset biotechs — companies with one drug in clinical development — a clinical hold can trigger a broader restructuring. The board may replace the CEO. Investors may demand leadership changes as a condition of continued funding. This makes clinical holds a source of C-suite search mandates, not just functional leadership changes.
Roles & Who to Contact
Roles This Intelligence Triggers: Chief Medical Officer (CMO), VP of Clinical Development, VP of Drug Safety/Pharmacovigilance, Director of Clinical Operations, VP of Regulatory Affairs, VP of Quality (if manufacturing-related hold), CEO (at single-asset companies).
Who to Approach: CEO or Board Chair — clinical holds are board-level events. CSO or CMO for safety-related leadership changes. VP of Quality for manufacturing-related holds.
How to Track It
Clinical holds are not published in a single FDA database, but they surface through multiple free channels. ClinicalTrials.gov shows study status changes — a study that moves from "Recruiting" to "Suspended" or "Terminated" may indicate a clinical hold. Company SEC filings (8-K for material events, 10-K risk factors) disclose clinical holds as material events.
BioSpace and Fierce Biotech cover clinical hold announcements as breaking news. Set Google Alerts for "clinical hold" + "FDA" to catch announcements in real time. Cross-reference with LinkedIn to assess the company's current clinical and safety leadership. Processing takes 1 hour per week.
Check the company's recent funding history (Intelligence 1). A single-asset biotech on a clinical hold that raised its last round 18+ months ago may be running low on cash — which means the clinical hold may trigger a restructuring (Intelligence 13) rather than a remediation. Both outcomes create search mandates.
A Complete Response Letter (CRL) is the FDA's formal rejection of a drug application (NDA/BLA). It means the drug is not approved and the company must address the FDA's concerns before resubmitting. A CRL is a major setback that typically causes stock price drops of 30-70% for publicly traded biotechs, triggers immediate leadership reviews, and often leads to restructuring. The hiring impact cuts both ways — some roles are eliminated, but remediation and resubmission create new leadership needs.
Why This Matters
A CRL indicates that the FDA found deficiencies serious enough to prevent approval — inadequate clinical data, manufacturing quality issues, labelling concerns, or safety concerns. The company must decide whether to conduct additional clinical trials (adding 1-3 years and hundreds of millions in cost), address manufacturing deficiencies, or abandon the programme entirely.
The leadership fallout is predictable. If the CRL cites clinical data deficiencies, the VP of Clinical Development and Head of Biostatistics are under scrutiny. If it cites manufacturing issues, the VP of Quality and VP of Manufacturing are at risk. If the company decides to restructure rather than resubmit, the CEO may be replaced by the board.
For search partners, the CRL creates two windows: an immediate crisis window (leadership replacements) and a 3-6 month rebuilding window (hiring the team to address the CRL and prepare a resubmission).
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Clinical Development, VP of Regulatory Affairs, Head of CMC (if manufacturing-related CRL), VP of Biostatistics, VP of Quality, Chief Medical Officer, CEO (if board loses confidence), VP of Corporate Communications/Investor Relations.
Who to Approach: Board Chair for CEO-level changes. CEO for VP-level replacements. General Counsel for compliance and regulatory leadership. Lead investor for portfolio company CRL situations.
How to Track It
CRLs are disclosed by companies through SEC 8-K filings (material events) and press releases. The FDA does not publish CRLs directly, though recent policy discussions have debated increasing transparency. BioSpace and Fierce Biotech cover CRL announcements as major news.
Monitor PDUFA dates (Intelligence 5) — a CRL arrives on or near the PDUFA date. When a PDUFA date passes without an approval announcement, a CRL is likely. Check SEC EDGAR for 8-K filings from the company on or after the PDUFA date. Processing is event-driven — monitor PDUFA dates and check for outcomes.
Cross-reference with Intelligence 13 (Mass Layoff/Restructuring). A company that receives a CRL and announces layoffs within 30-60 days is restructuring around its remaining pipeline — the new leadership team will be hired through retained search.
When the FDA issues a device recall — especially Class I (most serious) or Class II — the manufacturer faces immediate regulatory, legal, and operational pressure. A recall triggers leadership reviews in quality, regulatory, post-market surveillance, and manufacturing.
Why This Matters
Device recalls are published on the FDA's recall database and categorised by severity. Class I recalls — where there is a reasonable probability that use of the product will cause serious adverse health consequences or death — are the most impactful.
The quality and regulatory leadership responsible for the failed device is almost always replaced. A Class I recall triggers VP of Quality and VP of Regulatory replacements within 60-90 days.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Quality, Director of Post-Market Surveillance, Director of CAPA, Director of Complaints, VP of Regulatory Affairs, Director of Design Quality, Quality Remediation Lead.
Who to Approach: CEO or COO — recalls are executive-level crises. General Counsel for recalls with potential litigation. Board member for Class I recalls.
How to Track It
FDA Recalls Database (fda.gov/medical-devices/medical-device-recalls) is searchable by company, product, date, and recall class. Search weekly for Class I and Class II device recalls.
Cross-reference the recalling company with LinkedIn to assess current quality leadership tenure. Processing takes 1 hour per week.
Check for MAUDE adverse event reports (Intelligence 18) in the months before the recall. A spike in adverse events followed by a recall suggests systemic quality failures.
The FDA's MAUDE database collects adverse event reports for medical devices. A sudden spike in adverse event reports for a specific device indicates a potential safety issue and often precedes a recall. More importantly for search partners, it indicates a post-market surveillance failure.
Why This Matters
MAUDE reports are submitted by manufacturers, healthcare facilities, and patients when a device malfunctions, causes injury, or contributes to a death. A spike indicates a systematic problem that the company's internal post-market surveillance should have detected.
Companies that miss adverse event trends face two consequences: regulatory enforcement (FDA can mandate a recall) and litigation (plaintiff attorneys monitor MAUDE for patterns). Both consequences create leadership pressure.
Roles & Who to Contact
Roles This Intelligence Triggers: Director of Post-Market Surveillance, Director of Complaints, VP of Quality (if the failure is systemic), Director of CAPA, Medical Safety Officer.
Who to Approach: VP of Quality or VP of Regulatory. CEO at smaller device companies.
How to Track It
MAUDE Database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm) is searchable by device name, manufacturer, event type, and date range.
Compare current month report volume to the 12-month average — a 2x+ increase warrants outreach. Processing takes 2-3 hours per month.
A MAUDE spike followed by a Warning Letter (Intelligence 7) within 12 months confirms systemic quality failure.
When a life sciences company files an S-1 (IPO) or merges with a SPAC, it transitions from a private company with informal structures to a public company with board governance, SEC reporting obligations, and institutional investor oversight. This transition creates a predictable set of corporate leadership hires: CFO, General Counsel, VP of Investor Relations, Chief Compliance Officer, and VP of HR. The S-1 filing is public on SEC EDGAR, often months before the IPO prices.
Why This Matters
Going public creates legal and governance requirements that private companies don't have. The company needs a CFO with public company experience, a General Counsel who can manage SEC filings and board governance, a VP of Investor Relations to manage Wall Street relationships, and a Chief Compliance Officer to oversee SOX compliance. These roles often don't exist at the private company stage.
The S-1 filing itself reveals the company's leadership gaps. Section "Executive Compensation" lists current executives. If there's no CFO, no General Counsel, and no VP of IR listed, those are confirmed vacancies that will be filled before or immediately after the IPO.
Roles & Who to Contact
Roles This Intelligence Triggers: Chief Financial Officer (public company experience), General Counsel, VP of Investor Relations, Chief Compliance Officer, VP of Human Resources, Corporate Secretary, Head of Internal Audit.
Who to Approach: CEO for CFO and General Counsel searches. Board Chair for governance roles. Lead underwriter (investment bank) sometimes has input on the CFO search.
How to Track It
SEC EDGAR Full-Text Search allows you to search for S-1 filings by date. Filter by SIC codes for pharma (2830-2836) and devices (3841-3842) to focus on life sciences.
Also monitor Fierce Biotech and BioSpace for IPO announcements, which are often covered as news. Cross-reference the S-1 with LinkedIn to identify which corporate roles are missing. Processing takes 1-2 hours per week.
Read the S-1's "Use of Proceeds" section. If the company says proceeds will fund a Phase III trial or commercial launch, layer with Intelligence 3 (Phase II→III) or Intelligence 5 (PDUFA Date) for the full picture of what operational leadership they'll need.
When a life sciences company is acquired — by a larger pharma, a PE firm, or through a merger — the integration creates a predictable set of leadership needs. The acquiring company needs integration leaders. The acquired company's existing leadership is reviewed and often replaced. New roles are created to combine operations, quality systems, regulatory filings, and commercial teams. M&A transactions are disclosed through SEC 8-K filings and press releases, often weeks before the deal closes.
Why This Matters
Life sciences M&A follows predictable patterns. A large pharma acquiring a biotech typically retains the R&D and clinical team but replaces corporate leadership (CEO, CFO, GC) with its own. A PE firm acquiring a CDMO installs its own operating partner, CFO, and often VP of Business Development. A merger of equals creates integration leadership roles — VP of Integration, Director of PMI (Post-Merger Integration), Chief Integration Officer.
The integration timeline is usually 12-18 months, with the most senior hires (C-suite at the combined entity) decided within 90 days of close. The volume of search mandates from a single large transaction can be significant — a $1B+ pharma acquisition can generate 10-20 VP and Director-level searches across the combined organisation.
Roles & Who to Contact
Roles This Intelligence Triggers: Chief Integration Officer, VP of Integration, Director of PMI, CFO (if the acquirer installs its own), VP of Corporate Development, VP of Operations (combined entity), VP of Quality (combined entity), VP of Regulatory (combined entity), Chief Commercial Officer (combined entity).
Who to Approach: CEO of the acquiring company for C-suite roles at the combined entity. PE operating partner for portfolio company acquisitions. Head of Corporate Development for integration leadership roles. Chief People Officer for broad integration hiring.
How to Track It
SEC EDGAR 8-K filings disclose material acquisitions. BioBucks (biobucks.com) tracks biopharma deal terms. Fierce Biotech and BioSpace cover M&A news.
Track announced deals and note the expected close date (usually disclosed in the press release). The integration hiring wave begins 30-60 days before close and continues for 12-18 months after. Processing takes 1-2 hours per week.
If the acquirer is a PE firm, check whether they've made other acquisitions in the same subsector (platform build strategy). A PE firm acquiring its third CDMO in 18 months will need the same integration playbook for each deal — and the same search partner.
When a life sciences company announces a significant layoff (typically 15%+ of workforce) or a strategic restructuring, it indicates a reset. The company is reorienting around its remaining pipeline, cutting functions it no longer needs, and — critically — rebuilding leadership around the new strategy. Restructurings create search mandates because the surviving organisation needs different leaders than the one that was downsized.
Why This Matters
Life sciences restructurings typically follow pipeline failures (CRL, clinical hold), funding constraints, or strategic pivots. The company eliminates roles aligned with the abandoned strategy and creates new roles aligned with the new one. The leadership team that oversaw the failure is often replaced as part of the restructuring.
Layoff trackers show that 60-70% of life sciences companies that conduct a major layoff hire a new CEO, CFO, or COO within 12 months. The restructuring creates an immediate window of uncertainty (bad for the people laid off) followed by a rebuilding window (good for search partners positioning for the new leadership team).
Roles & Who to Contact
Roles This Intelligence Triggers: CEO (new strategy), CFO (cost restructuring), Chief People Officer (managing the transition), VP of Corporate Development (new partnerships/licensing), VP of whatever function aligns with the new strategy.
Who to Approach: Board Chair for CEO changes. CEO for VP-level rebuilding. Lead investor for privately held companies. PE operating partner for portfolio company restructurings.
How to Track It
Fierce Biotech Layoff Tracker (fiercebiotech.com/biotech) tracks layoffs across biopharma. BioSpace Layoff Tracker (biospace.com/biospace-layoff-tracker) provides similar coverage. State WARN Act filings (required for layoffs of 100+ employees) are available through state labour department websites.
Monitor these trackers weekly. For each significant layoff (15%+ or 50+ employees), assess the company's pipeline and remaining strategy. Processing takes 1-2 hours per week.
Cross-reference with Intelligence 10 (CRL) or Intelligence 9 (Clinical Hold). A company that received a CRL, laid off its commercial team, and is now investing in a resubmission strategy will need new clinical and regulatory leadership for the resubmission.
When a life sciences company signs a significant licensing or partnership deal — exclusive rights to commercialise a drug in a territory, a co-development agreement for a medical device, or a technology licensing deal — it creates hiring demand for the capabilities needed to execute the agreement. These deals are disclosed in SEC 8-K filings and press releases.
Why This Matters
Licensing deals bring new products, technologies, or territories into a company's portfolio — but without the team to manage them. A company that licenses US commercial rights to a European oncology drug needs to build a US medical affairs, sales, and market access team from scratch.
The deal terms (disclosed in SEC filings) reveal the scope of hiring needed. An exclusive license with a $50M upfront payment and $200M in milestones is a serious commitment — the company will invest in the team to maximise returns.
Roles & Who to Contact
Roles This Intelligence Triggers: VP of Business Development (deal execution), VP of Commercial (new territory/product), Director of Medical Affairs (new therapeutic area), VP of Alliance Management, Director of Market Access (new product launch).
Who to Approach: CEO or VP of Business Development — they negotiated the deal and know the team requirements. CCO for commercial build-out roles.
How to Track It
SEC EDGAR 8-K filings disclose material licensing and partnership deals. Company press releases announce deals. Fierce Biotech and BioBucks track deal terms and milestones.
Monitor 8-K filings and industry news for licensing deals in your subsector. Assess the deal terms to determine the scale of hiring needed. Processing takes 1 hour per week.
If the licensing deal brings a late-stage pipeline asset (Phase III or NDA-ready), layer with Intelligence 5 (PDUFA Date) to understand the launch timeline.
Your Move
Everything in this guide describes real, trackable hiring intelligence across life sciences — the kind of predictive executive search business development intelligence that no job board, referral network, or conference relationship can match. The intelligence is there. The question is whether you want to track it yourself — or have it delivered to your desk.
Request a free intelligence brief for your desk. Delivered to your inbox within 24 hours.
Tell us your subsector and geography. We'll produce a desk-level intelligence brief — real intelligence, real companies, real hiring pressure — so you can see exactly what this looks like for your market.
We are not a search firm. We do not compete with you. We produce the intelligence that helps you win.
Request a Free Brief Book a Callforesightbridge.com — Kawsar Alam